Geron Discontinues Late-Stage Trial for Rare Blood Cancer Therapy
Geron said it will discontinue a late-stage trial for its therapy targeting a rare blood cancer. The halt raises questions about efficacy, potential path to approval, and the company’s remaining funding runway. Investors should expect near-term stock weakness as attention shifts to strategic options and asset valuation.
View signal analysis